Targeted Gene Therapy for Breast Cancer
Abstract
From the studies performed during the last one year, we determined the effects of AAV-mediated anti-angiogenic gene therapy as a combination therapy to chemotherapy. Based on the kinetics of rAAV transgene expression and the requirement of second-strand synthesis as a rate-limiting step, we continued our studies in a prevention model. Also we continued to use the cell line SKOV3.ipl instead of human breast cancer cell lines to avoid time delay due to slower growth kinetics in vivo. rAAV-encoding angiostatin and endostatin was injected prior to tumor cell implantation. Three weeks following vector administration, 10(exp6)SKOV3.ipl cells were implanted. Cohorts of mice also received no vector treatment, rAAV-GFP (non-specific vector control), chemotherapy alone, or a combination of rAAV endostatin+angiostatin and chemotherapy. Chemotherapy was administered during the first week after tumor implantation by intraperitoneal injection of 20 mg/kg taxol. Based on the results of these studies, we inferred the potential of AAV-mediated anti-angiogenic gene therapy in combination with chemotherapy. In the next year, we will determine whether such a combination therapy would provide regression of established tumors.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2004
- Accession Number
- ADA427915
Entities
People
- Selvarangan Ponnazhagan
Organizations
- University of Alabama